Statement Of Financial Position [Abstract]

Innate Pharma - Filing #5981200

Concept	As at 2024-12-31	As at 2024-12-31	As at 2024-12-31	As at 2024-12-31	As at 2024-12-31	As at 2024-12-31	As at 2024-12-31	As at 2024-12-31	As at 2023-12-31	As at 2023-12-31	As at 2023-12-31	As at 2023-12-31	As at 2023-12-31	As at 2023-12-31	As at 2023-12-31	As at 2023-12-31	As at 2022-12-31	As at 2022-12-31	As at 2022-12-31	As at 2022-12-31	As at 2022-12-31	As at 2022-12-31	As at 2022-12-31	As at 2022-12-31
Statement of financial position [abstract]
Assets [abstract]
Intangible assets other than goodwill	—	—	—	—	—	— EUR	—	—	416,000 EUR	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Trade and other receivables	—	—	—	—	—	14 300 EUR	—	—	66 111 EUR	—	—	—	—	—	—	—	52 445 EUR	—	—	—	—	—	—	—
Cash and cash equivalents	—	—	—	—	—	66 396 EUR	—	—	70 605 EUR	—	—	—	—	—	—	—	84 225 EUR	—	—	—	—	—	—	—
Assets	—	—	—	—	—	111 059 EUR	—	—	175 187 EUR	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Equity and liabilities [abstract]
Equity [abstract]
Issued capital	—	—	—	—	—	4 192 EUR	—	—	4 044 EUR	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Share premium	—	—	—	—	—	390 979 EUR	—	—	384 255 EUR	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Equity	336 893 EUR	390 979 EUR	4 192 EUR	1 018 EUR	1 045 EUR	8 834 EUR	27,000 EUR	49 471 EUR	51 901 EUR	329 323 EUR	7 570 EUR	1 009 EUR	384 255 EUR	4 044 EUR	514,000 EUR	495,000 EUR	54 151 EUR	272 213 EUR	58 103 EUR	615,000 EUR	819,000 EUR	379 637 EUR	4 011 EUR	204,000 EUR
Liabilities [abstract]
Trade and other payables	—	—	—	—	—	16 007 EUR	—	—	17 018 EUR	—	—	—	—	—	—	—	20 911 EUR	—	—	—	—	—	—	—
Equity and liabilities	—	—	—	—	—	111 059 EUR	—	—	175 187 EUR	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—